Education
About Us
Working with TipRanks
Follow Us
LENSAR (LNSR)
NASDAQ:LNSR
LNSR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.67 - $17.31
Previous CloseN/A
Volume40.10K
Average Volume (3M)184.72K
Market Cap
$166.72M
Enterprise Value$97.90M
Total Cash (Recent Filing)$16.26M
Total Debt (Recent Filing)$2.61M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
May 07, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.72
Shares Outstanding11,790,440
10 Day Avg. Volume297,663
30 Day Avg. Volume184,721
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.27
Price to Cash Flow (P/CF)11.90
P/FCF Ratio11.90
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.79
Enterprise Value/Ebitda-32.58
Forecast
1Y Price Target
$15.00Price Target Upside6.08% Upside
Rating ConsensusHold
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company reported Q4 revenue of $16.7M, which was 38% higher than the previous year and above market expectations.
International ExpansionLNSR's expansion into the EU and Southeast Asia is expected to drive international growth.
Market AdoptionLensar has been seeing strong adoption of its ALLY technology, with a significant portion of new system placements coming from new customers.
Bears Say
Growth ChallengeLensar is required to achieve substantial procedure growth to meet the terms of the acquisition agreement, which may pose challenges.
ProfitabilityGross margins are lower due to higher capital sales, which impacts the company's profitability.
ValuationThe stock is rated as Neutral because the implied takeout value is seen as fairly valued, indicating limited upside potential.
---
Ownership Overview
40.41% Insiders
9.37% Mutual Funds
15.07% Other Institutional Investors
30.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LNSR FAQ
What was LENSAR’s price range in the past 12 months?
LENSAR lowest stock price was $2.67 and its highest was $17.31 in the past 12 months.
What is LENSAR’s market cap?
LENSAR’s market cap is $166.72M.
When is LENSAR’s upcoming earnings report date?
LENSAR’s upcoming earnings report date is May 07, 2025 which is in 40 days.
How were LENSAR’s earnings last quarter?
LENSAR released its earnings results on Feb 27, 2025. The company reported -$1.61 earnings per share for the quarter, missing the consensus estimate of -$0.182 by -$1.428.
Is LENSAR overvalued?
According to Wall Street analysts LENSAR’s price is currently Undervalued.
Does LENSAR pay dividends?
LENSAR does not currently pay dividends.
What is LENSAR’s EPS estimate?
LENSAR’s EPS estimate is -0.15.
How many shares outstanding does LENSAR have?
LENSAR has 11,790,440 shares outstanding.
What happened to LENSAR’s price movement after its last earnings report?
LENSAR reported an EPS of -$1.61 in its last earnings report, missing expectations of -$0.182. Following the earnings report the stock price went up 14.784%.
Which hedge fund is a major shareholder of LENSAR?
Currently, no hedge funds are holding shares in LNSR
---
LENSAR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.00 (6.08% Upside)
$15.00 (6.08% Upside)
Blogger Sentiment
Bullish
LNSR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 45.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.7%
Last 30 Days ▲ 61.0%
Last 30 Days ▲ 61.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
299.43%
12-Months-Change
Fundamentals
Return on Equity
-95.42%
Trailing 12-Months
Asset Growth
-4.73%
Trailing 12-Months
Company Description
LENSAR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
---
LNSR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance in 2024, with record-breaking revenue growth, significant market share gains, and positive adjusted EBITDA. However, there is a notable decrease in recurring revenue percentage and a substantial net loss due to a non-cash charge. The company remains optimistic about future growth and market expansion.Read More>---
LNSR Stock 12 Month Forecast
Average Price Target
$15.00
▲(6.08% Upside)
Technical Analysis
Align Tech
―
ICU Medical
―
EyePoint Pharmaceuticals
―
Staar Surgical
―
National Vision Holdings
―
Best Analysts Covering LNSR
1 Year
1 Year Success Rate
10/17 ratings generated profit
1 Year Average Return
+42.22%
reiterated a buy rating 24 days ago
Copying Ryan Zimmerman's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +42.22% per trade.
---